Skip to Content

Soliton, Inc.

Merger

  • Date:
  • 5/11/2021
  • Company Name:
  • Soliton, Inc.
  • Stock Symbol:
  • SOLY
  • Company Name - Buyer:
  • AbbVie, Inc.
  • Stock Symbol - Buyer:
  • ABVV
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 5/10/2021

Case Finder

Locate any case using the tools below.

NEW YORK, May 11, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Soliton, Inc. (NASDAQ: SOLY) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by AbbVie, Inc. (NYSE: ABVV).

On May 10, 2021, Soliton announced that it had signed an agreement to be acquired by AbbVie for approximately $550 million.  Pursuant to the merger agreement, Soliton stockholders will receive $22.60 in cash for each share of Soliton common stock owned. 

Bragar Eagel & Squire is concerned that Soliton’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Soliton’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Soliton. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: